Skye Bioscience Inc.

On Monday May 13th, Skye Bioscience's CEO and Chair Punit Dhillon will present an overview of the company at the Citizens JMP Securities Life Sciences Conference 2024. Listen live at 11:30 am ET or to the recording afterwards by registering here: https://lnkd.in/gDSZSds4

Skye is limitless and we are excited to announce we are growing our team 🚀 We are looking for a Senior Clinical Research Scientist to join our R&D team to help develop, plan and execute clinical biomarker studies. This person will be reporting to our Chief Scientific Officer, Chris Twitty, and be responsible for reviewing, analyzing and presenting clinical trial data from metabolic studies. This is an exciting time to join our fast growing team. Use the link below to apply! https://lnkd.in/gxg4T-ky

“Our mission at Skye is very simple. We’re absolutely interested in developing precision therapeutics and pharmaceuticals that help patients.” Skye Bioscience Inc. CEO Punit Dhillon reflects on the clinical-stage biotechnology company’s mission and how being #NasdaqListed helps them to deliver on that mission.

The $SKYE is limitless for Skye Bioscience Inc. as they celebrate their recent listing at the Nasdaq Opening Bell. 🛎️✨ $SKYE is a pharmaceuticals company developing proprietary molecules to treat diseases involving inflammatory, fibrotic and metabolic conditions. Congratulations! #NasdaqListed 👏

After uplisting to the Nasdaq Global Market last week, Skye Bioscience, Inc. will be ringing the Nasdaq bell this Thursday, April 18 at 6:30am PST/9:30am EST! Join us as we mark this exciting milestone in our journey. Stay tuned for the broadcasting link to watch live, coming tomorrow morning! Nasdaq Exchange #SkyeBioscience #NasdaqBellRing

Skye Bioscience has uplisted to the Nasdaq Global Market, a significant step mirroring its fundamental accomplishments, fundamental life science investors, and capital raised in in the last quarters. We now look forward to reporting Phase 2 glaucoma data in Q2 and starting the Phase 2 obesity study for our CB1 inhibitor in Q3. For additional details, read the full press release here: http://bit.ly/40nVSNO

Skye looks forward to talking about its Phase 2 for its novel glaucoma therapeutic at Eyecelerator

Skye has announced that it's entered into a securities purchase agreement for the sale of 4,000,000 shares of its common stock at $10.00 per share to certain investors in a private placement (the "PIPE") to certain qualified institutional buyers. Gross proceeds from the PIPE are expected to be $40 million before deducting any placement agent fees and offering-related expenses. The PIPE financing is expected to close on March 13, 2024, subject to the satisfaction of customary closing conditions.   Read the full story here: https://bit.ly/4c4SFsl

Skye has announced that it's entered into a securities purchase agreement for the sale of 4,000,000 shares of its common stock at $10.00 per share to certain investors in a private placement (the "PIPE") to certain qualified institutional buyers. Gross proceeds from the PIPE are expected to be $40 million before deducting any placement agent fees and offering-related expenses. The PIPE financing is expected to close on March 13, 2024, subject to the satisfaction of customary closing conditions.   Read the full story here: https://bit.ly/4c4SFsl

We welcome industry leader, Dr. Annalisa Jenkins, MBBS, FRCP, to our Board of Directors. Dr. Jenkins has broad experience in building and leading teams and developing strategies that have resulted in the advancement of new products across multiple disease areas from discovery through to clinical development, regulatory approval, and commercialization worldwide. Dr. Jenkins previously held senior leadership roles at Merck Serono Pharmaceuticals and Bristol Myers Squibb. For additional details, read the full press release here https://bit.ly/3Pb7YWr